image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 27.38
-2.7 %
$ 862 M
Market Cap
14.72
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one COLL stock under the worst case scenario is HIDDEN Compared to the current market price of 27.4 USD, Collegium Pharmaceutical, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one COLL stock under the base case scenario is HIDDEN Compared to the current market price of 27.4 USD, Collegium Pharmaceutical, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one COLL stock under the best case scenario is HIDDEN Compared to the current market price of 27.4 USD, Collegium Pharmaceutical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart COLL

image
$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
631 M REVENUE
11.41%
170 M OPERATING INCOME
1.76%
69.2 M NET INCOME
43.68%
205 M OPERATING CASH FLOW
-25.39%
-288 M INVESTING CASH FLOW
-306.37%
-60.6 M FINANCING CASH FLOW
56.77%
182 M REVENUE
14.22%
38.1 M OPERATING INCOME
9.39%
12.5 M NET INCOME
34.29%
84.6 M OPERATING CASH FLOW
1040.59%
-11.8 M INVESTING CASH FLOW
95.28%
-41.3 M FINANCING CASH FLOW
-27.70%
Balance Sheet Collegium Pharmaceutical, Inc.
image
Current Assets 482 M
Cash & Short-Term Investments 163 M
Receivables 229 M
Other Current Assets 91 M
Non-Current Assets 1.18 B
Long-Term Investments 0
PP&E 20.2 M
Other Non-Current Assets 1.16 B
9.78 %13.74 %5.47 %69.80 %Total Assets$1.7b
Current Liabilities 510 M
Accounts Payable 3.93 M
Short-Term Debt 65.9 M
Other Current Liabilities 440 M
Non-Current Liabilities 925 M
Long-Term Debt 793 M
Other Non-Current Liabilities 132 M
4.59 %30.65 %55.30 %9.19 %Total Liabilities$1.4b
EFFICIENCY
Earnings Waterfall Collegium Pharmaceutical, Inc.
image
Revenue 631 M
Cost Of Revenue 254 M
Gross Profit 377 M
Operating Expenses 207 M
Operating Income 170 M
Other Expenses 101 M
Net Income 69.2 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00631m(254m)377m(207m)170m(101m)69mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.76% GROSS MARGIN
59.76%
26.91% OPERATING MARGIN
26.91%
10.96% NET MARGIN
10.96%
30.23% ROE
30.23%
4.16% ROA
4.16%
9.78% ROIC
9.78%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Collegium Pharmaceutical, Inc.
image
300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 69.2 M
Depreciation & Amortization 163 M
Capital Expenditures -1.65 M
Stock-Based Compensation 32.4 M
Change in Working Capital 0
Others -33.1 M
Free Cash Flow 203 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Collegium Pharmaceutical, Inc.
image
Wall Street analysts predict an average 1-year price target for COLL of $41.9 , with forecasts ranging from a low of $36 to a high of $50 .
COLL Lowest Price Target Wall Street Target
36 USD 31.48%
COLL Average Price Target Wall Street Target
41.9 USD 52.87%
COLL Highest Price Target Wall Street Target
50 USD 82.62%
Price
Max Price Target
Min Price Target
Average Price Target
505045454040353530302525May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Collegium Pharmaceutical, Inc.
image
Sold
0-3 MONTHS
4.89 M USD 3
3-6 MONTHS
909 K USD 1
6-9 MONTHS
1.13 M USD 2
9-12 MONTHS
6.09 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. globenewswire.com - 2 weeks ago
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. globenewswire.com - 3 weeks ago
Collegium Announces Updates to its Board of Directors and Executive Leadership Team – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman  and Gwen A. Melincoff, Board Member to Retire from Board – globenewswire.com - 1 month ago
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025. globenewswire.com - 1 month ago
Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025 Collegium Pharmaceutical Inc. is a specialty pharma company with strong cash flow, high EBITDA margins, and a focus on non-abusive painkillers and ADHD drugs. The new CEO has a proven track record, previously growing Horizon's revenue from $300 million to $4 billion and selling it to Amgen for $28 billion. The stock is undervalued at 4.5x EBITDA 2024, with potential for re-rating as Jornay PM ramps up and reduces the impact of Nucynta's exclusivity loss. seekingalpha.com - 1 month ago
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare Conference Tuesday, March 11, 2025 Jefferies Biotech on the Beach Summit Wednesday, March 12, 2025 Barclays 27 th Annual Global Healthcare Conference Thursday, March 13, 2025 About Collegium Pharmaceutical, Inc. Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. globenewswire.com - 1 month ago
Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Vikram Karnani - President & Chief Executive Officer Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.58 per share a year ago. zacks.com - 1 month ago
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM ® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7  Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. globenewswire.com - 1 month ago
Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Collegium Pharmaceutical (COLL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 1 month ago
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. globenewswire.com - 2 months ago
8. Profile Summary

Collegium Pharmaceutical, Inc. COLL

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 862 M
Dividend Yield 0.00%
Description Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Contact 100 Technology Center Drive, Stoughton, MA, 02072 https://www.collegiumpharma.com
IPO Date May 7, 2015
Employees 357
Officers Ms. Jane Gonnerman Executive Vice President of Strategy & Corporate Development Mr. Dean J. Patras Chief People Officer Mr. David Dieter Executive Vice President, General Counsel & Corporate Secretary Mr. Scott Sudduth Head of Technical Operations